These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28444254)

  • 1. The Effect of Biosimilars [Inflectra®] in the Management of Acute Severe Ulcerative Colitis.
    Harkin G; Keogh Á; Slattery E
    J Crohns Colitis; 2017 Oct; 11(11):1400-1401. PubMed ID: 28444254
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Clinical Outcomes After Switching from Remicade
    Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
    Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study.
    Petitdidier N; Tannoury J; de'Angelis N; Gagniere C; Hulin A; Rotkopf H; Mesli F; Brunetti F; Sobhani I; Amiot A
    Dig Liver Dis; 2019 Dec; 51(12):1652-1660. PubMed ID: 31718934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SB2: An Infliximab Biosimilar.
    Lamb YN; Scott LJ; Deeks ED
    BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar.
    Kidd DP; Galloway M; Wilhelm T
    Neurology; 2020 Jun; 94(22):991-993. PubMed ID: 32393649
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Henoch-Schönlein purpura complicating infliximab therapy for ulcerative colitis.
    Laresche C; Locatelli F; Biver-Dalle C; Nachury M; Heyd B; Koch S; Aubin F
    Cutis; 2017 Jan; 99(1):E20-E22. PubMed ID: 28207014
    [No Abstract]   [Full Text] [Related]  

  • 11. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
    Mizoshita T; Katano T; Tanida S; Hirano A; Miyaki T; Ozeki K; Suzuki Y; Sugimura N; Kataoka H; Joh T
    Medicine (Baltimore); 2017 Aug; 96(32):e7800. PubMed ID: 28796080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.
    Lawrance IC
    Expert Opin Investig Drugs; 2015 Jun; 24(6):761-8. PubMed ID: 25719407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
    Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
    Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.